Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
AHA 25: Beta-Blocker Therapy Post MI in Patients with Preserved LVEF
Author(s): Anna Meta Dyrvig Kristensen Added: 2 months ago
AHA Scientific Sessions 2025 – Dr Anna Meta Dyrvig Kristensen (Copenhagen University Hospital, Bispebjerg and Frederiksberg, DK) presents an individual patient data meta-analysis examining beta-blocker therapy after myocardial infarction in patients with preserved left ventricular ejection fraction.This comprehensive meta-analysis pooled individual patient data from five randomized controlled… View more

Heart Failure
ESC 25 Hot Line Discussion: BETAMI-DANBLOCK: Beta-Blockers after MI
Author(s): Harriette Van Spall , Dan Atar , Anna Meta Dyrvig Kristensen Added: 5 months ago
ESC Congress 2025 - Long-term beta-blocker therapy after myocardial infarction reduced the primary endpoint of death from any cause or major adverse cardiovascular events.Late-breaker host Dr Harriette Van Spall (McMaster University, CA) sits down with Prof Dan Atar (Oslo University Hospital Ulleval, NO) and Dr Anna Meta Dyrvig Kristensen (Bispebjerg and Frederiksberg Hospital, DK) to discuss the… View more

Heart Failure

MI/ACS
ESC 25: The REBOOT-CNIC Trial
Author(s): Borja Ibanez Added: 5 months ago
ESC Congress 2025 - REBOOT-MI finds that beta-blocker therapy after MI did not reduce the occurrence of adverse events in patients with LVEF greater than 40%.Dr Borja Ibanez (National Centre for Cardiovascular Research, Madrid, ES) joins us to discuss findings from REBOOT-CNIC (NCT03596385). The prospective, randomised, open-label trial investigated the benefits of long-term betablocker therapy… View more

Heart Failure

MI/ACS
ESC 24 Hot Line Discussion: The AβYSS Trial
Author(s): Harriette Van Spall , Prof. Johanne Silvain Added: 1 year ago
ESC Congress 2024 — The interruption of beta blocker treatment was not non-inferior to a strategy of βB continuation.Host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) sits down with investigator, Prof Johanne Silvain(Pitié-Salpêtrière University Hospital, Paris, FR) to discuss key results from the AβYSS trial (NCT03498066; Assistance Publique - Hôpitaux de Paris).The ABYSS trial… View more

MI/ACS
Non-invasive Coronary Functional Tests in ANOCA
Author(s): Nello Cambise , Angelo Giuseppe Marino , Fabio De Benedetto , et al Added: 2 weeks ago

Imaging & Diagnostics

Prevention & Chronic Conditions
ESC 25: 4 Heart Failure Trials That Will Change My Practice
Author(s): Michelle Kittleson Added: 5 months ago
ESC Congress 2025 - In this video, Dr Michelle Kittleson (Cedars-Sinai Heart Institute, US) outlines the hot-line data from the congress that are expected to have an impact on clinical practice in the heart failure space.Trials covered in detail include:REBOOT-CNIC: Beta-Blockers after Myocardial Infarction without Reduced Ejection FractionBETAMI-DANBLOCK: Beta-Blockers after Myocardial… View more

Anticoagulation

Heart Failure
Job title: Clinical Professor of Medicine and Pharmacology
Yield and Characterisation of CFT in ANOCA
Author(s): Johanna McChord , Astrid Hubert , Udo Sechtem , et al Added: 1 year ago

Prevention & Chronic Conditions
Job title: Professor of Anesthesiology and Physiology
Treatment of Hypertrophic Cardiomyopathy with Dr Tiku Owens
Author(s): Anjali T Owens Added: 4 months ago
Navigate the rapidly evolving treatment landscape for hypertrophic cardiomyopathy with Dr Anjali Tiku Owens, a renowned expert in inherited cardiovascular diseases and advanced heart failure.This comprehensive presentation, part of the Cardiomyopathies track of Women As One's CLIMB® 2025 Skills Training Program, explores both established and emerging therapeutic approaches for obstructive and non… View more

Heart Failure